PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics’ CEO’s disciplined 10(b)(5)(1) trades reveal steady insider confidence, a new share‑repurchase program and potential upside for long‑term investors.

CEO trades reveal confidence in Protagonist Therapeutics’ upside: buys low, sells high as stock hits 52‑week highs, hinting at future growth.

Waddill William D. buys low and sells high in Protagonist Therapeutics, signaling confidence in the biotech’s peptide‑based pipeline and future upside.

Insider buying by Protagonist Therapeutics’ director signals confidence in its peptide pipeline; low‑impact trade hints at future upside.

Protagonist Therapeutics insider Waddill buys 9,000 shares below market, showing cautious optimism amid a pipeline‑driven upside.

Protagonist Therapeutics CEO buys 75,000 shares at $21.58 while selling 75,000 at $100.12— a dual strategy that signals long‑term confidence yet manages liquidity and risk.

Protagonist Therapeutics insider trades show routine liquidity moves, not strategic bets—learn how Molina’s buy‑sell pattern affects investors and share price volatility.

Protagonist Therapeutics CEO Dinesh Patel’s March trades reveal a strategic portfolio shuffle rather than a confidence drop, but watch Rule 144 filings for potential liquidity‑driven moves.

Protagonist Therapeutics CEO Dinesh Patel’s recent sale of 50,000 shares amid rising stock highlights insider trading patterns and investor caution.

Insider buying at Protagonist Therapeutics shows confidence in its peptide drug pipeline and hints at a potential price rally ahead.